Relay Therapeutics, Inc.

NasdaqGM:RLAY Stock Report

Market Cap: US$708.0m

Relay Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RLAY Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Oct 24SellUS$10,284Thomas CatinazzoIndividual1,697US$6.06
28 Oct 24SellUS$9,823Peter RahmerIndividual1,621US$6.06
28 Oct 24SellUS$9,890Brian AdamsIndividual1,632US$6.06
28 Oct 24SellUS$16,289Donald BergstromIndividual2,688US$6.06
27 Sep 24SellUS$4,866Donald BergstromIndividual648US$7.51
27 Sep 24SellUS$2,215Brian AdamsIndividual295US$7.51
27 Sep 24SellUS$2,215Thomas CatinazzoIndividual295US$7.51
27 Sep 24SellUS$1,840Peter RahmerIndividual245US$7.51
29 Jul 24SellUS$14,496Brian AdamsIndividual1,638US$8.85
29 Jul 24SellUS$23,877Donald BergstromIndividual2,698US$8.85
29 Jul 24SellUS$12,027Peter RahmerIndividual1,359US$8.85
29 Jul 24SellUS$15,063Thomas CatinazzoIndividual1,702US$8.85
27 Jun 24SellUS$1,847Brian AdamsIndividual295US$6.26
27 Jun 24SellUS$1,847Thomas CatinazzoIndividual295US$6.26
27 Jun 24SellUS$1,534Peter RahmerIndividual245US$6.26
27 Jun 24SellUS$4,056Donald BergstromIndividual648US$6.26
03 Jun 24SellUS$128,520Peter RahmerIndividual19,864US$6.47
29 Apr 24SellUS$17,137Donald BergstromIndividual2,686US$6.38
29 Apr 24SellUS$10,814Thomas CatinazzoIndividual1,695US$6.38
29 Apr 24SellUS$10,355Brian AdamsIndividual1,623US$6.38
29 Apr 24SellUS$8,581Peter RahmerIndividual1,345US$6.38
27 Mar 24SellUS$2,295Peter RahmerIndividual298US$7.70
27 Mar 24SellUS$2,680Brian AdamsIndividual348US$7.70
27 Mar 24SellUS$5,891Donald BergstromIndividual765US$7.70
27 Mar 24SellUS$2,680Thomas CatinazzoIndividual348US$7.70
29 Jan 24SellUS$19,328Thomas CatinazzoIndividual2,005US$9.64
29 Jan 24SellUS$15,916Peter RahmerIndividual1,651US$9.64
29 Jan 24SellUS$18,596Brian AdamsIndividual1,929US$9.64
29 Jan 24SellUS$30,636Donald BergstromIndividual3,178US$9.64

Insider Trading Volume

Insider Buying: RLAY insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of RLAY?
Owner TypeNumber of SharesOwnership Percentage
Public Companies4,5800.00274%
Individual Insiders2,773,6171.66%
General Public3,229,0111.93%
VC/PE Firms37,156,07122.2%
Institutions124,219,67974.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.8%.

Top Shareholders

Top 25 shareholders own 75.4% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.7%
SB Investment Advisers (UK) Limited
27,904,963US$118.0m0%0.62%
8.64%
The Vanguard Group, Inc.
14,463,614US$61.2m23.6%no data
7.02%
BlackRock, Inc.
11,742,147US$49.7m11.4%no data
5.53%
Casdin Capital, LLC
9,251,108US$39.1m9.5%2.56%
4.41%
Bellevue Asset Management AG
7,377,184US$31.2m15.7%0.38%
3.16%
JP Morgan Asset Management
5,286,019US$22.4m41.4%no data
3.15%
T. Rowe Price Group, Inc.
5,280,291US$22.3m4.79%no data
2.57%
State Street Global Advisors, Inc.
4,300,216US$18.2m1.22%no data
2.3%
Nextech Invest Ltd.
3,846,409US$16.3m0%2.74%
2.13%
Tang Capital Management, LLC
3,568,058US$15.1m0%1.11%
2.09%
Braidwell LP
3,499,427US$14.8m16.4%0.67%
1.98%
Norges Bank Investment Management
3,319,342US$14.0m0%no data
1.74%
Citadel Advisors LLC
2,909,371US$12.3m150%0.01%
1.63%
Geode Capital Management, LLC
2,732,270US$11.6m15.5%no data
1.6%
Eventide Asset Management, LLC
2,682,083US$11.3m0%0.2%
1.49%
EcoR1 Capital, LLC
2,500,000US$10.6m0%0.36%
1.21%
BioImpact Capital LLC
2,033,041US$8.6m59.5%1.46%
1.09%
Walleye Capital LLC
1,819,983US$7.7m6,660%0.06%
1.09%
Tavistock Life Sciences
1,819,132US$7.7m0%0.54%
1.04%
Dimensional Fund Advisors LP
1,748,663US$7.4m15%no data
1.04%
Point72 Asset Management, L.P.
1,736,517US$7.3m0%0.02%
0.99%
Adage Capital Management, L.P.
1,650,000US$7.0m0%0.01%
0.97%
Finepoint Capital LP
1,626,146US$6.9m1.3%0.81%
0.93%
GV Management Company, LLC
1,564,173US$6.6m0%0.44%
0.92%
First Light Asset Management, LLC
1,542,406US$6.5m0%0.59%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:05
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Relay Therapeutics, Inc. is covered by 16 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Gaurav GoparajuBerenberg
Jason Matthew GerberryBofA Global Research